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Previews2000; Rodgers and Shiozawa, 2008). By
demonstrating that phenylalanyl-tRNA
synthetases can misacylate tRNAPhe
with L-DOPA, Moor et al. (2011) provide
a fourth pathway for incorporating
L-DOPA into proteins (Figure 1). This
new pathway may be particularly relevant
to proteins synthesized by the mitochon-
dria, given the inability of the mitochon-
drial phenylalanyl-tRNA synthetase to
hydrolyze misacylated tRNAPhe.
Incorporation of L-DOPA through misa-
cylation of tRNAPhe is distinct from the
other known mechanisms for incorpo-
rating L-DOPA into proteins, as it replaces
a phenylalanine residue, whereas in the
other three mechanisms L-DOPA re-
places tyrosine. As a result, it should be
possible to quantify the extent to which
misacylation of tRNAPhe results in the
incorporation of L-DOPA into proteins
in vivo. Furthermore, since the efficiency
of tRNAmisacylation by L-DOPA appears1202 Chemistry & Biology 18, October 28, 20to be similar for the phenylalanyl- and
tyrosyl-tRNA synthetases, misincorpora-
tion of L-DOPA in place of phenylalanine
may also provide an estimate for the
frequency with which L-DOPA incorpora-
tion is due to misacylation of tRNATyr.
Given that L-DOPA is currently the most
commonly prescribed drug for Parkin-
son’s disease, it is imperative to deter-
mine the extent to which tRNA mis-
acylation is responsible for the elevated
levels of L-DOPA-containing proteins
found in patients treated with this drug
(Rodgers et al., 2006). The article by
Moor et al. (2011) in this issue of
Chemistry & Biology provides a way to
address this question.REFERENCES
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Photoactivatable fluorescent proteins are now widely used for cell and protein tracking and super-resolution
optical imaging. In this issue, Adam et al. (2011) report a general approach to introduce photochromism into
green-to-red photoconvertible proteins and describe newphotoactivatable protein with a complex four-state
flasher-like behavior and advanced characteristics.Green fluorescent protein (GFP) from
jellyfish Aequorea victoria and its nu-
merous mutants and homologs from di-
verse marine creatures possess a unique
type of posttranslational modifications—
a chromophore group formed via self-
catalyzed reactions from its own internal
amino acids (Chudakov et al., 2010). As
a result, GFP-like fluorescent proteins
(FPs) become fluorescent by themselves,
with no help of external enzymes or co-
factors except molecular oxygen. This
extraordinary ability makes it possible to
use FPs as fully genetically encoded
labels to mark specific cells, cell organ-
elles, and proteins and monitor processin live systems. Nowadays, they are an
indispensable toolkit in experimental
biology, which is used in thousands of
studies each year.
A particularly interesting and useful
group of FPs is photoactivatable FPs
(PAFPs) capable of drastically increasing
their fluorescence in a specific spectral
region in response to illuminationwith light
of specific wavelength and intensity (Chu-
dakov et al., 2010). There are two main
types of such proteins—irreversible and
reversible PAFPs. Proteins of the first
type photoconvert once from one state
to another due to irreversible photochem-
ical reactions of the chromophore (e.g.,extension of its conjugated p-system)
and/or surrounding amino acids (e.g.,
decarboxylation of a Glu residue) (Mizuno
et al., 2003; Chudakov et al., 2010). PAFPs
of the second type canbephotoconverted
multiple times due to cis-trans isomeri-
zation of the chromophore and/or re-
versible reactions such as protonation-
deprotonation and hydration-dehydration
(Chudakov et al., 2003, 2010; Brakemann
et al., 2011).
One of the first irreversible PAFPs
was green-to-red photoconvertible FPs
called Kaede (after the Japanese word
for maple leaf) (Ando et al., 2002). This
green FP becomes red after illumination
Figure 1. An Outline of Photoconversions of IrisFP-Like Fluorescent
Proteins
Fluorescent protein b-barrels are colored correspondingly to fluorescence of
different states, switching between which can be achieved by illumination
with light of specific wavelength and intensity (arrows). These four-state pho-
toswitchable proteins resemble an emergency flasher with blinking green and
red beacons.
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Previewswith UV or violet light (at
around 400 nm). A number of
Kaede-like proteins were
generated, namely, EosFP,
Dendra, mKikGR, and their
improved variants. In 2008,
a mutant of EosFP called
IrisFP was created (Adam
et al., 2008). IrisFP shows
complex spectral behavior
combining both reversible
and irreversible photoconver-
sions (Figure 1). In its initial
green fluorescent state, IrisFP
can be reversibly switched off
and on by cyan (approxi-
mately 490 nm) and violet
(approximately 400 nm) light,
respectively. Strong illumina-
tion with violet light results
in irreversible conversion of
IrisFP into red fluorescent
state. Red IrisFP in turn
undergoes reversible photo-
switching between fluores-
cent and dark states upon
illumination with green (ap-
proximately 540 nm, On-to-Off) and blue (approximately 440 nm,
Off-to-On) light.
In the current issue of Chemistry &
Biology, Adam et al. (2011) demonstrate
that such on/off photochromism can be
introduced in virtually any green-to-red
photoconvertible fluorescent protein by
rational point mutagenesis at key posi-
tions. This work represents a logical con-
tinuation of previous investigations of
mechanisms of reversible photoconver-
sions in PAFPs. When the first reversibly
switchable PAFPs, a chromoprotein
asFP595 from sea anemone Anemonia
sulcata and its variants such as KFP1,
were discovered, it was found that photo-
switching between dark and red fluores-
cent states is mainly controlled by a few
residues around chromophore, suggest-
ing cis-trans isomerization of the chromo-
phore during photoconversion (Chudakov
et al., 2003). Further mutagenesis and
structural studies with different fluores-
cent proteins confirmed and extended
this concept. Importance of additional
residues was revealed (Adam et al.,
2008). Although exact influence of each
amino acid substitution still cannot be
predicted, construction of a few mutants
was sufficient to find variants with IrisFP-
like phenotype (Adam et al., 2011). Inparticular, single F173S mutation in
Dendra2 resulted in excellent photo-
chromic behavior. This protein named
NijiFP, after the Japanese word for rain-
bow, possesses advanced characteris-
tics, such as monomeric state, efficient
green-to-red photoconversion and rever-
sible photoswitching in both states, high
fluorescence brightness, and high photo-
stability. NijiFP appears to be a very
promising PAFP for advanced imaging
applications.
How to take advantage of PAFPs
in imaging? The most straightforward
application is to track movements of
objects of interest (cells, cell organelles,
or proteins). Light beam can be strictly
controlled in space and time giving an
opportunity of precise photolabeling with
PAFPs. Second major field of PAFPs’
applications emerged recently with intro-
duction of super-resolution fluorescence
microscopy technologies, which enable
imaging down to 10–20 nm scale resolu-
tion (Chudakov et al., 2010). PAFPs
can be also used to extend possibilities
of imaging with multiple labels since
PAFPs can be discriminated by their
photoconversion behavior (Chudakov
et al., 2003; Andresen et al., 2008), to
establish photochromic FRET (ForsterChemistry & Biology 18, October 28, 2011 ª2011 Elseviresonance energy transfer)
with reversibly switchable
acceptor (Subach et al.,
2010), to track the degrada-
tion of a protein of interest
(Zhang et al., 2007), or to
discriminate target signal
from noise (Marriott et al.,
2008). As demonstrated by
Adam et al. (2011) the newly
introduced NijiFP can be
successfully used to track
diffusion of a target protein
and obtain super-resolution
images. Moreover, its four-
state spectral behavior allows
combining both tracking and
super-resolution imaging for
the same object. NijiFP is
likely well suitable for photo-
chromic FRET as its absorp-
tion spectra for both green
and red states can be revers-
ibly changed, although this
is yet to be demonstrated.
Again, due to combination
of irreversible green-to-red
conversion and reversiblephotoswitching, it is tempting to propose
the use of NijiFP for simultaneous obser-
vation of target protein movements
and its interaction with other proteins.
Generally, sophisticated photoactivation
scheme of NijiFP calls for new ideas and
new questions to be solved by advanced
microscopy.REFERENCES
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Libraries of diverse small molecules are important to probe and drug discovery. The current trend toward
building massive screening collections to support drug development, a special application of chemical
biology, can limit their broader potential. Biology-driven construction methods (Wallace et al., 2011) are
rapidly emerging to bring chemical libraries back on a viable path.When the label of a prescription medicine
reads ‘‘inactive ingredients 98%,’’ it is
telling you the vast majority of substances
in the pills are inert, and that is an impor-
tant and acceptable method of preparing
a drug for administration. However, in
compound libraries designed for chemi-
cal biology, inertness, with apt pharmaco-
kinetics (PK)/pharmacodynamics or not,
is an undesirable filler. Considerable effort
is made to maximize the potential for
bioactivity in modern screening libraries.
Although no one claims to know exactly
which compounds are bioactive in any
particular system, data-driven models
may help select the bright sparks from
the dim bulbs.
The study conducted by Wallace et al.
(2011 [this issue of Chemistry & Biology])
represents an important step toward es-
tablishing a dichotomy between thera-
peutic drug and biological probe discov-
ery. For the most part, probe and drug
development has historically been ap-
proached from the same canonical meth-
odologies and central paradigms. How-
ever, with significantly different goals, it
would seem logical to use divergent paths
and starting points. For example, in library
design, blanket application of Lipinski’s
rule of five (Ro5), and derivatives thereof,
represents the status quo for compoundlibrary selection. Ro5, intended to maxi-
mize the proportion of bioavailable small
molecule agents, has been applied to
guide most commercial and academic
library development (Dolle, 2011). The re-
ality today is that scientists seeking small
molecules as probes to study a target of
interest are relying on compound librar-
ies designed to maximize favorable PK
in human/animal subjects. Compounds
based on peptide-like sequences (Koda-
dek, 2010), privileged structures, and
natural products (Welsch et al., 2010) are
examples of useful chemical probes that
generally fall outside of the Ro5 criteria.
Clearly, the Ro5 along with many other
general compound attributes are desir-
able for therapeutic drug discovery (Over-
ington et al., 2006). Who would want their
drug screening results to be dominated
by unstable molecules with poor PK?
Models developed to guide the popula-
tion of screening libraries are needed, if
not marginally to simplify high-throughput
screening (HTS) logistics and costs, then
importantly to accommodate novel tech-
nology and methodology. In this respect,
the design of chemical libraries is more
valuable than the sheer size. The results
in Wallace et al. (2011) demonstrate, not
unexpectedly, that the Ro5 may not al-
ways be the ideal filter for compoundslikely to be useful in chemical biology.
A completely new set of compound
selection principles may maximize the
chemical space most relevant to non-
or pretherapeutic applications. After all,
the Wright brothers didn’t include a pres-
surized cabin on their flying machine;
why add drag before you even get off
the ground? Wallace and colleagues
move beyond generic property filters to
develop models for bioactive molecule
characteristics. This is an evolving con-
cept in biology-driven library construction
(Basu et al., 2011) that focuses on struc-
tural signatures instead of generic de-
scriptors (such as calculated solubility
partition coefficients, e.g., cLogP and
molecular weight). In an examination of
publicly available screening data sets,
their Bayesian model showed promise in
enriching for the most active hits.
Given the value of probe molecules
to basic research, a fundamental rethink-
ing of the methodologies used in
such efforts is warranted. The Wallace
et al. (2011) presents timely and immedi-
ately useful ideas for chemical biology.
While the academic efforts to develop
therapeutically relevant small molecules
continue to show promise worldwide,
their research to aid in the discovery of
flexible and titratible tools (probes) that
